Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
09/18/2017 09/19/2017 09/20/2017 09/21/2017 09/22/2017 Date
243.7(c) 244.8(c) 247(c) 249(c) 248(c) Last
1 000 392 1 309 826 1 366 536 1 389 627 1 041 874 Volume
+0.21% +0.45% +0.90% +0.81% -0.40% Change
More quotes
Financials ( CHF)
Sales 2017 53 361 M
EBIT 2017 18 314 M
Net income 2017 11 181 M
Debt 2017 8 848 M
Yield 2017 3,46%
Sales 2018 55 569 M
EBIT 2018 19 450 M
Net income 2018 12 431 M
Debt 2018 4 810 M
Yield 2018 3,65%
P/E ratio 2017 18,52
P/E ratio 2018 16,86
EV / Sales2017 4,17x
EV / Sales2018 3,93x
Capitalization 214 B
More Financials
Company
Roche Holding AG operates as a research healthcare company.It operates through the following segments: Diagnostics and Pharmaceuticals.The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience.The... 
Sector
Pharmaceuticals
Calendar
09/27Presentation
More about the company
Surperformance© ratings of Roche Holding Ltd.
Trading Rating : Investor Rating :
More Ratings
Latest news on ROCHE HOLDING LTD.
09/22 ROCHE : receives EU approval of TECENTRIQ® (atezolizumab) in a specific type of ..
09/22 ROCHE : unloads another plant in deal with Recipharm that saves 200 jobs
09/22 ROCHE : receives EU approval of Gazyvaro for people with previously untreated ad..
09/22 ROCHE : receives European approval for Actemra /RoActemra in giant cell arteriti..
09/21 HALOZYME THERAPEUTICS : Licenses New Enhanze Target For $30 Million Upfront Paym..
09/21 ROCHE : Best way to counter Diabetes is Healthy Diet, Exercise and constant moni..
09/21 ROCHE : Spanish plant becomes eighth solid dose site for Recipharm
09/21 ROCHE : Invitation to Roche's 9 Months Sales 2017 Audio Webcast and Conference C..
09/20 ABBVIE : and Roche plan Venclexta combo filings in leukaemia
09/20 ROCHE : FDA locks down combo immunotherapy trials, Roche added to hold
More news
Sector news : Pharmaceuticals - NEC
09/22DJCorrection to Sept. 7 Harvey Rebuilding Article
09/22 Korea tensions keep European shares in check before Germany vote
09/22 Bettencourt death stirs speculation about L'Oreal ownership
09/22 China online insurer ZhongAn prices Hong Kong IPO at top end, raises $1.5 bil..
09/21DJPFIZER : Files Antitrust Lawsuit Against J&J -- WSJ
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on ROCHE HOLDING LTD. 
ROCHE HOLDING LTD. - 2016
An opportunity over the medium term?
BUY
ROCHE HOLDING LTD. - 2016
A medium term support level to take advantage of
BUY
More Strategies
Latest Tweets
09/22#Space #Art: hitting the "Roche Limit" by @dblasphemy
11
09/22  
09/22Roche receives EU approval for Gazyvaro, European approval for Actemra
2
09/22Expanded use of Roche's Gazyvaro OK'd in Europe  
09/22Roche's Actemra/RoActemra OK'd in Europe for giant cell arteritis  
More tweets
Qtime:142
News from SeekingAlpha
09/22 Expanded use of Roche's Gazyvaro OK'd in Europe
09/22 Roche's Actemra/RoActemra OK'd in Europe for giant cell arteritis
09/21 FDA's Woodcock says clinical trials system "broken"
09/20 Daily OTC Markets Round-Up - 9/19/2017
09/19 YOUR DAILY PHARMA SCOOP : Nabriva's Further Potential, Allergan's IP Gimmick, Su..
Chart ROCHE HOLDING LTD.
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | ROG | CH0012032048 | 4-Traders
Technical analysis trends ROCHE HOLDING LTD.
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 277  CHF
Spread / Average Target 12%
EPS Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.6.19%220 358
JOHNSON & JOHNSON15.63%353 617
NOVARTIS11.88%223 850
PFIZER10.81%214 206
MERCK AND COMPANY11.75%178 914
SANOFI9.06%126 655